Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm atezolizumab in PD-L1-positive advanced NSCLC
2013-000177-69Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Primary endpoint: Investigator-assessed overall response rate (ORR) per modified RECIST. Started Aug 2013; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-000177-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000177-69.